4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine

We are 4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine CAS:1197953-49-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine
CAS.NO:1197953-49-3
Synonyms:2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl]-4-pyrimidinamine
Molecular Formula:C12H12Cl2N3OP
Molecular Weight:316.12300
 
Specification:
Appearance:White powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Brigatinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine


Related News: The data will be updated at the upcoming 2019 ASH Annual Meeting next week.espiro [1-azabiciclo [2.2.2] octano-3,2'-oxirano] CAS:41353-91-7 Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.Glycine ethyl ester hydrochloride CAS:623-33-6 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.51437-00-4 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.

Related Products
Product Name
1-(4-Iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one View Details
N-methyl pyridinium methyl sulfate View Details
(3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione View Details
2-Anilinoethanol manufacturer 5-amino-2-methylphenol,sulfuric acid manufacturer 5-Ethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine manufacturer methyl 3-bromo-2-fluorobenzoate manufacturer L-Leucine manufacturer